Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen induces exon 51 skipping, thereby producing a shorter but functional dystrophin protein. The longest available data are from an open-label extension study (PRO051-02) treating 12 boys with drisapersen (6 mg/kg/week subcutaneously). The median change (range) from baseline to week 177 in six-minute walking distance (6MWD) was 8 (-263, 163) metres. The current analysis aimed to put the results from PRO051-02 in the context of natural progression by comparing the functional trajectory of drisapersen-treated subjects to a matched natural history (NH) cohort, treated by standard of care. Subjects were matched individually by age and 6MWD, as the prima...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
<div><p>Background</p><p>Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing an...
THERAPY DEVELOPMENT AND CLINICAL OUTCOME MEASURES FOR DUCHENNE MUSCULAR DYSTROPHY SUMMARY Duchenne m...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Deficits in ambulatory function progress at heterogeneous rates among individuals with Duchenne musc...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affect...
BackgroundDrisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthe...
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated effica...
INTRODUCTION: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were follo...
<div><p>The 6 minute walk test has been recently chosen as the primary outcome measure in internatio...
High variability in patients' changes in 6 minute walk distance (6MWD) over time has complicated cli...
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated effica...
Objective: The aim of the study was to assess different outcome measures in a cohort of ambulant boy...
BACKGROUND: Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease p...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
<div><p>Background</p><p>Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing an...
THERAPY DEVELOPMENT AND CLINICAL OUTCOME MEASURES FOR DUCHENNE MUSCULAR DYSTROPHY SUMMARY Duchenne m...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Deficits in ambulatory function progress at heterogeneous rates among individuals with Duchenne musc...
Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is...
The aim of the study was i) to assess the spectrum of changes over 24 months in ambulant boys affect...
BackgroundDrisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthe...
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated effica...
INTRODUCTION: Duchenne muscular dystrophy (DMD) subjects ≥5 years with nonsense mutations were follo...
<div><p>The 6 minute walk test has been recently chosen as the primary outcome measure in internatio...
High variability in patients' changes in 6 minute walk distance (6MWD) over time has complicated cli...
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated effica...
Objective: The aim of the study was to assess different outcome measures in a cohort of ambulant boy...
BACKGROUND: Duchenne muscular dystrophy (DMD) exhibits substantial variability in rates of disease p...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
<div><p>Background</p><p>Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing an...
THERAPY DEVELOPMENT AND CLINICAL OUTCOME MEASURES FOR DUCHENNE MUSCULAR DYSTROPHY SUMMARY Duchenne m...